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Although only 1.5% of the human genome appears to
code for proteins, much effort in cancer research has been
devoted to this minimal fraction of our DNA. However,
the last few years have witnessed the realization that
a large class of non-coding RNAs (ncRNAs), named
microRNAs, contribute to cancer development and
progression by acting as oncogenes or tumor suppressor
genes. Recent studies have also shown that epigenetic
silencing of microRNAs with tumor suppressor features by
CpG island hypermethylation is a common hallmark of
human tumors. Thus, we wondered whether there were
other ncRNAs undergoing aberrant DNA methylation-
associated silencing in transformed cells. We focused on
the transcribed-ultraconserved regions (T-UCRs), a sub-
set of DNA sequences that are absolutely conserved
between orthologous regions of the human, rat and mouse
genomes and that are located in both intra- and intergenic
regions. We used a pharmacological and genomic
approach to reveal the possible existence of an aberrant
epigenetic silencing pattern of T-UCRs by treating cancer
cells with a DNA-demethylating agent followed by
hybridization to an expression microarray containing
these sequences. We observed that DNA hypomethylation
induces release of T-UCR silencing in cancer cells. Among
the T-UCRs that were reactivated upon drug treatment,
Uc.160þ, Uc283þA and Uc.346þ were found to
undergo speciﬁc CpG island hypermethylation-associated
silencing in cancer cells compared with normal tissues.
The analysis of a large set of primary human tumors
(n¼283) demonstrated that hypermethylation of the
described T-UCR CpG islands was a common event
among the various tumor types. Our ﬁnding that, in
addition to microRNAs, another class of ncRNAs (T-
UCRs) undergoes DNA methylation-associated inactiva-
tion in transformed cells supports a model in which
epigenetic and genetic alterations in coding and non-
coding sequences cooperate in human tumorigenesis.
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Introduction
The best-studied sequences of the genome are protein-
coding genes, but their coding exons account for only
1.5% of the genome (2% if untranslated regions (UTRs)
are included) (International Human Genome Sequen-
cing Consortium, 2004). Thus, a large fraction of the
genome is constituted by non-protein-coding regions
that might have critical biological relevance (Mattick,
2003). The importance of this functional part of the
non-protein-coding genome is particularly apparent in a
large class of small, non-coding RNAs (ncRNAs), called
microRNAs (miRNAs; Ambros, 2004; Bartel, 2004;
He and Hannon, 2004; Mendell, 2005). These 19–24-
nucleotide transcripts regulate the expression of mes-
senger RNAs at the transcriptional and translational
levels by imperfect base pairing with the 30-UTR, the 50-
UTR and/or the coding region of the target (Miranda
et al., 2006; Iwama et al., 2007; Duursma et al., 2008).
In human cancer, recent studies have shown that miRNA
expression proﬁles differ between normal tissues and
derived tumors, and between tumor types (Calin et al.,
2004a; Lu et al., 2005; Volinia et al.,2 0 0 6 ) .m i R N A sc a n
act as oncogenes or tumor suppressors, exerting a key
function in tumorigenesis (Esquela-Kerscher and Slack,
2006; Hammond, 2007; Lujambio and Esteller, 2009).
Defects in miRNA function have been associated with a
failure of miRNA post-transcriptional regulation (Thom-
son et al., 2006), miRNA transcriptional repression by
oncogenic factors (Chang et al., 2008), loss-of-function
genetic alterations in miRNA-processing genes (Melo
et al., 2009) and, most interestingly, transcriptional silen-
cing associated with hypermethylation of CpG island
promoters (Saito et al., 2006; Han et al.,2 0 0 7 ;L u j a m b i o
et al., 2007, 2008; Toyota et al., 2008; Huang et al.,2 0 0 9 ) .
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www.nature.com/oncThus, as occurs with miRNAs, it is likely that other types
of ncRNAs are also involved in human tumorigenesis
and undergo epigenetic and genetic defects in this disease.
In this paper, we have focused on the possible DNA
methylation-associated silencing in human cancer cells of
another class of ncRNAs, transcribed-ultraconserved
regions (T-UCRs) (Bejerano et al., 2004; Calin et al.,
2007; Katzman et al.,2 0 0 7 ) .
Ultraconserved regions (UCRs) are a subset of
conserved sequences that are located in both intra-
and intergenic regions (Bejerano et al., 2004; Katzman
et al., 2007). They are absolutely conserved (100%)
between orthologous regions of the human, rat and
mouse genomes (Bejerano et al., 2004) and are strongly
constrained functional elements (Katzman et al., 2007).
The UCRs exhibit almost no natural variation in the
human population (Bejerano et al., 2004). In the human
genome, 481 sequences longer than 200bp that are
maximally conserved with orthologous segments in
rodents are deﬁned as UCRs (Bejerano et al., 2004).
Of these, 56% are non-exonic (without evidence of an
encoding protein), 23% are partly exonic (coincide with
the messenger RNA of a known human protein-coding
gene, including UTRs) and 21% are possibly exonic
(inconclusive evidence of overlap with protein-coding
genes). Much effort is currently being devoted to
unraveling the putative functions of UCRs, such as an
antisense regulatory role for protein-coding genes or
other ncRNAs, or a regulatory function as enhancers
(Nobrega et al., 2003; Pennacchio et al., 2006). The
majority (93%) of UCRs are transcribed (called T-UCRs)
in normal human tissues, both ubiquitously and in a
tissue-speciﬁc manner (Calin et al., 2007). Most impor-
tantly, recent data suggest that T-UCRs are altered at
the transcriptional level in human tumorigenesis and the
aberrant T-UCR expression proﬁles can be used to
differentiate human cancer types (Calin et al., 2007).
The downregulation of protein-coding genes, such as
many important tumor suppressor genes in human
cancer (Jones and Baylin, 2007; Esteller, 2008) and
miRNAs with growth-inhibitory functions (Lujambio
et al., 2007, 2008; Huang et al., 2009), has been tightly
linked to the presence of CpG island promoter
hypermethylation. Therefore, we wondered whether
the same mechanism could have a role in the loss of
adequate T-UCR expression in tumors. Herein, we
present a pharmacological and genomic unmasking of
T-UCR CpG islands that undergo cancer-speciﬁc
hypermethylation-associated transcriptional silencing,
such as Uc.160þ, Uc283þA and Uc.346þ,i nt h e
most common types of human cancer. These ﬁndings
support a model in which epigenetic disruption of
emerging new classes of ncRNAs, such as T-UCRs,
constitutes a hallmark of human tumorigenesis.
Results
To identify T-UCRs with putative DNA methylation-
related inactivation in human tumors, we followed the
experimental algorithm shown in Figure 1. First, we
treated the human colorectal cancer cell line HCT-116
with the DNA methylation inhibitor 5-aza-20-deoxy-
cytidine. To measure T-UCR levels, total RNA was
extracted before and after treatment with the DNA-
demethylating drug in each case, and proﬁled using our
previously validated UCR platform (Calin et al., 2007).
This UCR microarray chip includes a total of 481
human UCR sequences longer than 200bp (Bejerano
et al., 2004). T-UCRs can be transcribed from one
strand (sense or antisense) or bidirectionally (Calin
et al., 2007). In total, two 40-mer probes were designed
for each UCR: one corresponding to the sense genomic
sequence (named ‘þ’) and the other to the comple-
mentary sequence (named ‘þA’). Thus, 962 possible
T-UCRs can be studied using this approach. Our
pharmacological screening revealed that 14 of 481
(2.9%) human UCRs printed on the microarray had
minimal basal expression in the untreated cells and
X2.25log2 (ratio between geometric means of intensity)
upregulation upon use of 5-aza-20-deoxycytidine (Sup-
plementary Table 1). Of these 14 signiﬁcantly upregu-
lated T-UCRs, 6 (42.9%) had one canonical CpG island
within a 2000-bp distance upstream in the transcrip-
tional sense of that particular T-UCR: Uc.283þA,
Uc.346þ, Uc.160þ, Uc.282þA, Uc.469þAa n d
Uc.392þA (Supplementary Table 1). The studied
length likely covers most of the CpG islands with a
T-UCR microarray
HCT-116-AZA vs HCT-116
(481 UCRs represented)
14 T-UCRs
Minimal expression in HCT-116 and
upregulation in AZA-treated cells
6 T-UCRs
Presence of CpG island within
2,000 base pairs upstream the
ultraconserved region
CpG island methylated in HCT-116
5 T-UCRs
Cancer specific methylation
(unmethylated in normal colon)
3 T-UCRs
Uc.160+    Uc.283+A    Uc.346+
Figure 1 Schematic strategy used to unmask DNA methylation-
associated repression of T-UCRs in colon cancer cells. AZA, 5-aza-
20-deoxycytidine.
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Oncogenepossible impact on T-UCR expression because T-UCR
length has been described to range between 0.8 and
1.8kb (Calin et al., 2007).
To demonstrate the presence of CpG island methyla-
tion in these six upregulated T-UCRs upon DNA
demethylation treatment, we undertook bisulﬁte geno-
mic-sequencing analyses of multiple clones in the HCT-
116 colorectal cancer cell line from which the T-UCR
expression microarray data were obtained. We found
dense DNA methylation in 5 of 6 (83.3%) of the
described CpG island-associated T-UCRs: Uc.283þA,
Uc.346þ, Uc.160þ, Uc.282þA and Uc.469þA
(Figures 2a and b; Supplementary Figure 1), whereas
Uc392þA was found to be unmethylated in HCT-116
cells (Supplementary Figure 2). We wanted to focus on
the cancer-speciﬁc DNA methylation changes; hence we
used bisulﬁte genomic sequencing to analyze the DNA
methylation status of these remaining ﬁve T-UCR-
associated CpG islands in normal colon mucosa (n¼5),
to exclude tissue-speciﬁc DNA methylation patterns.
The expression of many T-UCRs is different according
to cell type (Calin et al., 2007); hence it was not
surprising to observe that 2 of 5 (40%) of these T-UCR-
associated CpG islands, Uc.282þA and Uc.469þA,
were also densely methylated in normal colorectal
mucosa (Supplementary Figure 1). However, and most
importantly, the CpG islands for Uc.160þ, Uc.283þA
and Uc.346þ were always unmethylated in all normal
Uc.160+
HCT-116
DKO
NC
NL
3´ 5´
HCT-116
DKO
NC
NL
Uc.346+
3´ 5´
HCT-116
DKO
NC
NL
UMUM UMUM U M
DKO NC H2O
Uc.346+
UMUMUMUM UM
HCT-116 DKO NC
Uc.160+
UMUMU M UM UM
DKO IVD H2O
Uc.283+A
HCT-116 HCT-116
Uc.283+A
3´ 5´
-107 +218
-1403
-1001 +135
-1299 -885 -189
-308
-582
IVD NL H2O
M M
NC NL
M
IVD NL
Figure 2 CpG island methylation of T-UCRs in colon cancer cell lines and normal tissues. (a) Bisulﬁte genomic sequencing of the
associated CpG islands for the T-UCRs Uc.160þ, Uc.283þA and Uc.346þ in the colorectal cancer cell lines HCT-116 and DKO,
normal colon (NC) and normal lymphocytes (NL). CpG dinucleotides are represented as short vertical lines and the location of the
T-UCR probe from the expression microarray is represented as a black arrowhead. The locations of the bisulﬁte genomic sequencing
primers are indicated by black arrows. Eight single clones are represented for each sample. Presence of a methylated or unmethylated
cytosine is indicated by a black or a white square, respectively. For Uc.283þA and Uc.346þ, two regions within the CpG island were
analyzed. The transcription start sites identiﬁed by RACE are represented by vertical black arrows. (b) Methylation-speciﬁc PCR
analyses for Uc.160þ, Uc.283þA and Uc.346þ methylation in the colorectal cancer cell lines HCT-116 and DKO, normal colon
(NC) and normal lymphocytes (NL). Unmethylated (U) or methylated (M) sequences. In vitro methylated DNA (IVD) is shown as a
positive control for methylated sequences. The locations of the methylation-speciﬁc PCR primers are indicated in panel ‘a’ by gray
arrows.
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Oncogenetissues studied (Figures 2a and b). The DNA methyla-
tion results were also conﬁrmed using methylation-
speciﬁc PCR (Figure 2b).
To demonstrate the transcriptional silencing of these
T-UCRs in cancer cells in association with the presence
of CpG island hypermethylation, we measured T-UCR
levels by quantitative reverse transcriptase (RT)–PCR.
The expression of Uc.160þ, Uc.283þA and Uc.346þ
transcripts was not detectable in HCT-116 cells showing
CpG island methylation of the corresponding CpG
island (Figure 3a). Most importantly, a restoration of
T-UCR expression was observed upon treatment with
the DNA-demethylating agent (Figure 3a). These results
were conﬁrmed using an alternative model, speciﬁcally
an isogenic HCT-116 cell line in which the two major
DNA methyltransferases, DNMT1 and DNMT3b, had
been genetically disrupted (HCT116 DKO) (Rhee et al.,
2002). The CpG islands for Uc.160þ, Uc.283þA and
Uc.346þ were unmethylated in DKO cells, although
they were hypermethylated in its parental cell line,
HCT116 (Figures 2a and b). Most importantly, restora-
tion of Uc.160þ, Uc.283þA and Uc.346þ expression
was observed in DKO cells (Figure 3a), reinforcing the
link between CpG island hypermethylation and T-UCR
silencing.
DNA methylation silencing of tumor suppressor
genes (Nguyen et al., 2002; Ballestar et al., 2003;
McGarvey et al., 2008; Jacinto et al., 2009) and
microRNAs with growth-inhibitory functions (Saito
et al., 2006; Lujambio et al., 2007) is closely linked to
chromatin modiﬁcations. To determine active vs in-
active expression, we analyzed by chromatin immuno-
precipitation the presence of a histone modiﬁcation
mark associated with active transcription, trimethyla-
tion of lysine 4 of histone H3 (Esteller, 2007), in these T-
UCRs in HCT-116 cells. Uc.160þ, Uc.283þA and
Uc.346þ CpG island hypermethylation was accompa-
nied by the absence or minimal presence of trimethyla-
tion of lysine 4 of histone H3 (Figure 3b). This histone
mark was present in the studied T-UCR CpG islands in
DKO cells or upon treatment of HCT-116 cells with the
DNA-demethylating agent (Figure 3b). Furthermore,
because DNA methylation and histone tail modiﬁca-
tions crosstalk with nucleosome positioning in tran-
scriptional regulation (Henikoff, 2007, 2008), we
wondered whether T-UCR CpG island methylation
silencing is also associated with a less accessible local
chromatin conformation, as it occurs for hypermethy-
lated CpG islands of tumor suppressor genes (Lin et al.,
2007). We examined chromatin accessibility in the
Uc.160þ, Uc.283þA and Uc.346þ CpG islands using
nuclei isolated from HCT-116 cells with increasing
concentrations of the MspI restriction enzyme coupled
to real-time PCR. We observed that when Uc.160þ,
Uc.283þA and Uc.346þ CpG islands are hypermethy-
lated, these sites are inaccessible to the enzyme
(Figure 3c), but restoration of T-UCR expression
associated with CpG island demethylation upon 5-aza-
20-deoxycytidine treatment or in DKO cells results in
higher accessibility (Figure 3c). In addition, the un-
methylated T-UCR CpG islands were occupied by RNA
polymerase II that was not present in the hypermethy-
lated CpG islands (Figure 3d). In DKO cells or upon the
use of the DNA-demethylating drug, RNA polymerase
II occupancy for the studied T-UCR CpG islands was
restored (Figure 3d). Most importantly, we character-
ized the transcription start sites for the studied T-UCRs
using rapid ampliﬁcation of cDNA ends (RACE). For
Uc.160þ and Uc.283þA, the transcripts were origi-
nated within the studied corresponding CpG islands
(vertical black arrows in Figure 2a), while for Uc.346þ
transcription started just 189bp downstream of the CpG
island. Thus, our data suggest that expression of the
Uc.160þ, Uc.283þA and Uc.346þ transcripts occurs
in the context of an unmethylated CpG island, and
that cancer-speciﬁc hypermethylation of the described
T-UCR CpG islands is associated with transcriptional
silencing in a chromatin environment characteristic of
gene repression.
The presence of Uc.160þ, Uc.283þA and Uc.346þ
cancer-speciﬁc CpG island hypermethylation and tran-
scriptional silencing was not a unique feature of the
particular colorectal cancer cell line HCT-116, but upon
analyzing a large set of human cancer cell lines (n¼59)
from eight different tumor types, we observed that it
was commonly found in colon, breast, lung, lymphoma
and leukemia cells (Table 1). The T-UCR CpG island
methylation status was not associated with the K-ras
and p53 mutational status or the presence of micro-
satellite instability (Fisher’s exact test, P40.05). Quan-
titative RT–PCR studies in the leukemia cell line
MOLT-16 conﬁrmed that Uc.160þ, Uc.283þAa n d
Uc.346þ CpG island hypermethylation was associated
with loss of the corresponding T-UCR, while cells with
unmethylated CpG islands expressed these transcripts
(Figures 4a and b). We also conﬁrmed in MOLT-16 cells
that treatment with the demethylating agent restored T-
UCR expression (Figure 4b). Moreover, we used the
neuroblastoma cell line LAN-1, which was unmethy-
lated for all the three studied T-UCR CpG islands, to
further conﬁrm the association between an unmethy-
lated Uc.160þ, Uc.283þA and Uc.346þ CpG island
and expression of the corresponding transcript (Supple-
mentary Figure 3). We also performed chromatin
immunoprecipitation to obtain a detailed map of
RNA polymerase II occupancy in the three character-
ized T-UCRs in LAN-1 cells. We observed an enrich-
ment in RNA polymerase II in the corresponding
transcription start sites previously identiﬁed by RACE
(Supplementary Figure 3), reinforcing the link between
T-UCR-unmethylated 50-ends and active transcription.
Furthermore, we also used the T-UCR-unmethylated
neuroblastoma cell lines to study the cellular localiza-
tion of these transcripts. If mature microRNAs are
mostly located in the cytosol (Ambros, 2004; Bartel,
2004; He and Hannon, 2004), other non-coding RNAs
have been shown to localize in nucleus (Chen and
Carmichael, 2009). Using quantitative RT–PCR in
isolated nuclear and cytoplasmic fractions of the
neuroblastoma cell lines LAN-1, SK-N-SH and SK-N-
EB1, we have observed that Uc.160þ, Uc.283þAa n d
Uc.346þ CpG are almost exclusively localized in the
Hypermethylation of non-coding RNAs
A Lujambio et al
6393
OncogeneExpression
Uc.160+ Uc.283+A
10
0
2
4
6
8 8
10
0
2
4
6
8
10
0
2
4
6
ChIP H3K4me3
D
K
O
A
Z
A
H
C
T
-
1
1
6
H
C
T
-
1
1
6
D
K
O
A
Z
A
D
K
O
A
Z
A
H
C
T
-
1
1
6
R
e
l
a
t
i
v
e
 
u
n
i
t
s
0
5
10
15
20
25
30
H
C
T
-
1
1
6
D
K
O
A
Z
A 0
5
10
15
20
25
30
0
5
10
15
20
25
30
I
P
/
i
n
p
u
t
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
D
K
O
A
Z
A
H
C
T
-
1
1
6
MspI accessibility
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
D
K
O
A
Z
A
H
C
T
-
1
1
6
R
e
l
a
t
i
v
e
 
u
n
i
t
s
H
C
T
-
1
1
6
D
K
O
A
Z
A
H
C
T
-
1
1
6
D
K
O
A
Z
A
H
C
T
-
1
1
6
D
K
O
A
Z
A
ChIP RNA Pol II
I
P
/
i
n
p
u
t
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
0
H
C
T
-
1
1
6
D
K
O
A
Z
A
H
C
T
-
1
1
6
D
K
O
A
Z
A
H
C
T
-
1
1
6
A
Z
A
D
K
O
Uc.346+
Figure 3 T-UCR expression and chromatin environment. (a) Expression analyses of T-UCRs by quantitative RT–PCR. Uc.160þ,
Uc.283þA and Uc.346þ show minimal expression in the hypermethylated HCT-116 cells, while treatment with the DNA-
demethylating agent 5-aza-20-deoxycytidine (AZA) and DKO cells show T-UCR upregulation. (b) Quantitative chromatin
immunoprecipitation assay for the histone modiﬁcation mark trimethylation of lysine 4 of histone H3 (H3K4me3) that is associated
with active transcription. The presence of T-UCR CpG island methylation is associated with the lack of H3K4me3 histone, whereas
the opposite scenario is observed when DNA demethylation events are present by genetic disruption of the DNMTs (DKO cells) or
pharmacological treatment with a DNA-demethylating agent (AZA lane). (c) Chromatin accessibility assay using the MspI restriction
enzyme coupled to real-time PCR. The hypermethylated CpG islands of Uc.160þ, Uc.283þA and Uc.346þ CpG in HCT-116 are
inaccessible to the enzyme, but CpG island demethylation upon 5-aza-20-deoxycytidine treatment or in DKO cells results in higher
accessibility. (d) Quantitative chromatin immunoprecipitation assay for RNA polymerase II (RNA Pol II) shows its absence in T-UCR
hypermethylated CpG islands and its enrichment upon DNA hypomethylation events (DKO cells and HCT-116 treated with the
DNA-demethylating drug).
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Oncogenecytosol (Supplementary Figure 4). This ﬁnding might be
an important clue for further research focused on the
physiological roles of T-UCRs.
Most importantly, the CpG island hypermethylation
of Uc.160þ, Uc283þA and Uc.346þ was not an
in vitro phenomenon, because when we examined 283
human primary malignancies corresponding to six
different tissue types, we observed that Uc.160þ,
Uc.283þA and Uc.346þ CpG island hypermethyla-
tion was commonly found in primary colon, breast and
lung tumors, in addition to melanomas, leukemias and
lymphomas (Figures 5a and b). We conﬁrmed in a set of
corresponding normal tissues (ﬁfteen lung, two breast
and three lymphocyte samples), in addition to the
previously analyzed ﬁve colon mucosas, the absence of
hypermethylation of the described T-UCRs (Figures 4a
and 5b). For colorectal tumors, where K-ras and p53
mutational and microsatellite instability data were
available (Lujambio et al., 2007, 2008), the T-UCR
CpG island methylation status was not associated with
any of the described genetic alterations (Fisher’s exact
test, P40.05). To determine whether hypermethylation
of the described T-UCRs might represent an early lesion
in tumorigenesis, we examined the CpG island methyla-
tion status of Uc.160þ, Uc.283þA and Uc.346þ in
benign colorectal adenomas (n¼19), a lesion that is a
precursor to invasive colorectal tumors. We observed
that T-UCR hypermethylation is already present in these
premalignant lesions, although in a lower frequency to
that of established colon carcinomas (Figure 5b). How-
ever, the most compelling data regarding the role of
Uc.160þ, Uc.283þA and Uc.346þ epigenetic silencing
in tumor progression were obtained when the T-UCR
CpG island hypermethylation status was determined
with respect to the existence or non-existence of lymph
node metastasis in the tumors for which data were
available (Figure 5c). The presence of Uc.160þ,
Uc.283þA and Uc.346þ CpG island hypermethylation
in the primary tumor was signiﬁcantly associated with
those tumors that were positive for metastatic cancer
cells in the corresponding lymph nodes (Fisher’s exact
test; P¼0.0093, P¼1.366E 07 and P¼2.5818E 07,
respectively) (Figure 5c), which highlights the impor-
tance of the in vivo role of T-UCR epigenetic silencing in
tumorigenesis.
One of the main challenges in research into UCR (and
ncRNAs generally) is the identiﬁcation of a particular
cellular function. If tumor suppressor roles have been
described for coding genes (Jones and Baylin, 2007;
Esteller, 2008) and microRNAs (Davalos and Esteller,
2010) undergoing cancer-speciﬁc CpG island hyper-
methylation-associated silencing, T-UCRs might also
act in a similar manner. We have brieﬂy addressed
this issue by cloning the full length of the T-UCR
Uc.283þA (2227bp) and restoring its expression by
transfection in the hypermethylated and silenced HCT-
116 colorectal cancer cell line. Upon re-introduction of
Uc.283þA, we have observed a marked increase in the
cell-doubling time and a major enhancement in the
number of dead cells, assessed by the trypan blue and
cell cycle assays (Supplementary Figure 5). These results
suggest that the described hypermethylated T-UCRs
might have potential growth-inhibitory features that will
warrant further investigation.
Table 1 Proﬁle of T-UCR CpG island methylation status in human
cancer cell lines
Cell line Uc.160+ Uc.283+A Uc.346+ Tumor type
n o l o C 6 1 1 - T C H
SW-480
SW-620
RKO
LoVo
DLD-1
COLO 205
g n u L 9 4 5 - A
H23
H460
Calu-3
H441
H522
H358
EBC-1
H1299
t s a e r B 9 4 5 - T B
MCF-7
MDA-MB-157
SkBr3
MDA-MB-231
HCC1937
MDA-MB-436
CAMA-1
BT-474
UAC3199
a m o t s a l b o r u e N S 5 - I A L
LAN-1
SK-N-SH
SK-N-BE(2)
a i m e k u e L 0 6 - L H
Jurkat
KG-1a
Molt-16
SKNO1
REH
K562
KOPN-8
Molt-4
HEL 92.1.7
CMK
SD-1
SEM
MV-4-11
MOLM-13
a m o h p m y L s o m a R
Akata
Raji
Namalwa
Hut78
JeKo-1
U-937
Karpas-422
a m o c r a S 2 - s o a S
A-673
MG-63
CAL-78
a m o n a l e M 9 3   R G I
IGR 37
Black and white boxes indicate methylated or unmethylated CpG
island, respectively.
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OncogeneFrom a molecular genetics standpoint, untranscribed
UCRs might have regulatory functions as enhancers
(Nobrega et al., 2003; Pennacchio et al., 2006), while
myriad functions can be postulated for T-UCRs, such
as an antisense inhibitory role for protein-coding genes
or other ncRNAs, including miRNAs. We have
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Oncogenepreliminarily studied the possible effect of T-UCRs in
the expression of protein-coding genes located upstream
and downstream of the transcription start sites of
Uc.160þ, Uc.283þA and Uc.346þ (Supplementary
Table 3). The available microarray expression data that
compare HCT-116 vs DKO cells (Schuebel et al., 2007)
show that the expression of three T-UCR-surrounding
genes included in the described genomic platform
(AP3B1 for Uc.160þ; RFX4 for Uc.346þ; and ERCC6
for Uc.283þA) was unchanged in the DNA-hypo-
methylated cells. Thus, because DKO cells re-express the
T-UCRs characterized in our study and there is no effect
in the expression levels of the neighboring genes AP3B1,
RFX-4 and ERCC6, we can hypothesize that T-UCRs
exert their function at another level. The precise
molecular targets of these T-UCRs will be the focus of
future research in this area.
On the other hand, instead of T-UCRs acting on
protein-coding genes and miRNAs, it is possible that
miRNAs exert control over T-UCRs. Evidence support-
ing this contention comes from the demonstration that
many T-UCRs have signiﬁcant antisense complementarity
with particular miRNAs, the negative correlation between
expression of speciﬁc T-UCRs and predicted interactor
miRNAs, and the demonstration in a small subset of
T-UCRs of an interaction in vitro (luciferase assays) and
in vivo (miR transfection) with miR/T-UCR (Calin et al.,
2007). The latter observation is particularly relevant to
Uc.160þ, in which transfection of the oncogenic miR-
155 into leukemia cells signiﬁcantly reduced the expres-
sion level of Uc.160þ (Calin et al., 2007). Thus, if it is
widely accepted that the probability of simultaneous
hits in the same molecular pathway in a given tumor is
very low, simultaneous overexpression of miR-155 and
CpG island hypermethylation-associated inactivation
of Uc.160þ i nt h es a m el e u k e m i as a m p l es h o u l db ea
rare event. To test whether this inverse association
exists, we analyzed the association between miR-155
expression and Uc.160þ CpG island methylation status
in our 15 human leukemia cell lines. We observed an
unmethylated Uc.160þ CpG island in the leukemias with
high levels of the miR-155 transcript (n¼7) compared
with the presence of Uc.160þ hypermethylation in the
leukemias with low levels of miR-155 (n¼8) (P¼0.01492,
Student’s t-test) (Figure 5d). Thus, the mutual exclusivity
of the epigenetic alteration of Uc.160þ and the over-
expression of the oncogenic miR-155 suggests that they
may have a critical and cooperative role in human
leukemogenesis.
Discussion
The increasing number of cancer exonomes and
genomes sequenced exhibits a low rate of true genetic
mutations (Velculescu, 2008). Thus, there is a large
fraction of the genome constituted by non-coding DNA
sequences that is likely to contain genetic and epigenetic
defects in malignancies. The best example is the most
widely studied type of ncRNA, the microRNAs.
miRNA dysregulation has been found in many human
diseases, cancer being the paradigmatic example (Lu
et al., 2005; Calin and Croce, 2006; Volinia et al., 2006).
miRNA genetic alterations, such as deletions, mutations
and ampliﬁcations, have been increasingly found in
human tumors (Calin et al., 2004b; Zhang et al., 2006;
Rossi et al., 2008; Spizzo et al., 2009), and the miRNA
processing machinery can also be altered in transformed
cells (Zhang et al., 2006; Rossi et al., 2008; Merritt et al.,
2008; Hill et al., 2009; Melo et al., 2009). Most
importantly, miRNAs can also undergo cancer-speciﬁc
50-CpG island hypermethylation-associated silencing
(Saito et al., 2006; Han et al., 2007; Lujambio et al.,
2007, 2008; Toyota et al., 2008; Huang et al., 2009). We
have now provided data that suggest that DNA
methylation-associated silencing of miRNAs in human
cancer may be just the tip of the iceberg and that it
might be many more different classes of ncRNAs
undergoing epigenetic inactivation in transformed cells,
T-UCRs being the second prototypical example.
UCRs were discovered by bioinformatic comparisons
of the genomes of mouse, rat and human (Bejerano et al.,
2004). In total, 481 UCR sequences show 100% identity
among the three species. Some of them contain protein-
coding sequences, but over half are not predicted to code
for any protein (Bejerano et al., 2004). Using a custom-
designed microarray (Calin et al., 2007), a new class of
ncRNAs encoded from a subset of UCRs was identiﬁed:
transcribed UCRs (T-UCRs). These T-UCRs (also
called ultraconserved genes, UCGs) are expressed in
normal tissues with housekeeping and tissue-speciﬁc
patterns (Calin et al., 2007), in a similar manner as
protein-coding genes and miRNAs do. Interestingly, we
observed that while almost half of the T-UCR-associated
CpG islands are unmethylated in all tissues, the other
half show tissue-speciﬁc T-UCR CpG island methyla-
tion, as occurs with promoter CpG islands of coding
genes (Jones and Baylin, 2007; Esteller, 2008) and
miRNAs (Lujambio and Esteller, 2007, 2009). The
genome-wide expression proﬁle of T-UCRs reveals that
Figure 4 CpG island methylation and expression of T-UCRs in cancer cell lines and normal tissues. (a) Bisulﬁte genomic sequencing
of the associated CpG islands for the T-UCRs Uc.160þ, Uc.283þA and Uc.346þ in the leukemia cell line MOLT16 and normal
tissues (colon, NC; lymphocytes, NL; lung, Nlu-1 to Nlu-3). CpG dinucleotides are represented as short vertical lines and the location
of the T-UCR probe from the expression microarray is represented as a black arrowhead. The locations of the bisulﬁte genomic
sequencing primers are indicated by black arrows. Eight single clones are represented for each sample. Presence of a methylated or
unmethylated cytosine is indicated by a black or white square, respectively. The transcription start sites identiﬁed by RACE are
represented by vertical black arrows. (b) Expression analyses of T-UCRs by quantitative RT–PCR. Uc.160þ and Uc.346þ show
minimal expression in the hypermethylated MOLT-16 cells, while treatment with the DNA-demethylating agent 5-aza-20-deoxycytidine
(AZA) induces T-UCR upregulation. The Uc.283þA CpG island is unmethylated in MOLT-16 and the T-UCR is expressed at similar
levels in the untreated and demethylating agent-treated cells.
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Oncogenethese ncRNAs have distinct signatures in normal tissues
and human cancers, and between tumor types (Calin
et al., 2007). Many genetic defects could cause T-UCR
dysregulation in transformed cells, and, in fact, several of
these T-UCRs are located at fragile sites, ampliﬁed
regions and loss-of-heterozygosity loci (Calin et al.,
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Oncogene2004b; Zhang et al., 2006; Rossi et al., 2008). However, it
is reasonable to propose that they could also undergo
CpG island hypermethylation-associated silencing. Our
ﬁnding that epigenetic inactivation by CpG island
hypermethylation of a subset of T-UCRs, such as
Uc160þ, Uc.283þA and Uc.346þ, occurs in a wide
spectrum of human cancer cell lines and primary tumors
of varying cellular and tissue origin provides clear
support for the concept that major disruption of ncRNA
programming is a common feature of cancer cells.
An enormous task still lies ahead. New classes of
ncRNAs are emerging, such as piwi-interacting RNAs,
small-nucleolar RNAs, long ncRNAs, telomere-speciﬁc
small RNAs and transcription-initiation RNAs, that
might be subject to transcriptional regulation of
neighboring CpG islands and DNA methylation. The
particular functions of these ncRNAs are beginning to
be elucidated, but little is currently known about their
alteration in diseases such as cancer. However, it seems
likely that aberrations in the DNA methylation pattern
of their underlying genomic sequences will turn out to
have a role, and therefore merit further investigation.
For T-UCRs, once we have demonstrated their epige-
netic disturbance in human neoplasms, we will be in a
position to begin to understand their biological function
better. For untranscribed UCRs, previous studies have
suggested important roles in promoting the expres-
sion of several genes and in regulating alternative
splicing (Bejerano et al., 2004, 2006; Lareau et al.,
2007). However, for T-UCRs, which have a chromatin
context (histone modiﬁcations, chromatin accessibility
and RNA polymerase II occupancy) similar to that
observed in protein-coding genes and miRNAs depend-
ing on their transcriptional status, several functions are
still being studied.
In summary, our ﬁndings demonstrate that, in
addition to miRNAs, epigenetic silencing of other
classes of ncRNAs, such as T-UCRs, is a common
feature of human cancer. Our results not only provide
further valuable knowledge about the mechanisms
involved in normal and aberrant regulation of ncRNA
transcription, but also indicate that the tumor-speciﬁc
CpG island hypermethylated T-UCRs identiﬁed might
be useful biomarkers of the disease. Above all, the
reactivation of those T-UCRs that have undergone
aberrant CpG island hypermethylation in the trans-
formed cells might provide a new molecular basis for the
therapeutic use of pharmacological compounds with
DNA-demethylating activity in the treatment of cancer
patients.
Materials and methods
Cell lines, culture conditions and primary study samples
The 59 human cancer cell lines examined in this study were
obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and the German Collection of Micro-
organisms and Cell Cultures (DSMZ, Braunschweig,
Germany). HCT-116 and DKO cells were a generous gift
from Dr Bert Vogelstein (Johns Hopkins Kimmel Compre-
hensive Cancer Center, Baltimore, MD, USA). Cell lines were
treated with 1mM 5-aza-20-deoxycytidine (Sigma-Aldrich,
St Louis, MO, USA) for 48h to achieve demethylation
(Herman et al., 1998). Cell-doubling time, trypan blue assay
and cell cycle analysis were performed as described in
Supplementary Materials and methods. DNA samples from
primary tumors (n¼283), benign colorectal adenomas (n¼19)
and normal tissues (n¼25) were obtained at the time of the
clinically indicated surgical procedures. All patients gave
written consent to participate in the study and the Ethics
Committee of the different hospitals cleared the study protocol.
RNA isolation and T-UCR expression microarray analysis
Total RNA was isolated from the colorectal cancer cell line
HCT-116, before and after 5-aza-20-deoxycytidine treatment,
by Trizol extraction (Invitrogen, Carlsbad, CA, USA). T-UCR
microarray proﬁling was conducted as described (Calin et al.,
2007). Microarray chips were developed with a total of 481
human UCR sequences (Calin et al., 2007). For each UCR,
two 40-mer probes were designed, one corresponding to the
sense genomic sequence (named ‘þ’) and the other to the
complementary sequence (named ‘þA’). The design criteria
were as described (Liu et al., 2004). Each oligo was printed in
duplicate in two different slide locations, and therefore
quadruplicate numerical values were available for analysis.
Several thousand (3484) blank spots were used for background
subtraction. RNA extraction and microarray experiments,
consisting of the UCR microarray assembly, target prepara-
tion and array hybridization, were performed as described in
detail elsewhere (Calin et al., 2004a; Liu et al., 2004). Further
details are provided in Supplementary Materials and methods.
DNA methylation analyses
The CpG Island Searcher Program (Takai and Jones, 2003)
was used to determine which T-UCRs were located within a
±2000-bp proximity of a CpG island, as it has been predicted
that more than 90% of the human miRNA promoters are
located 1000bp upstream of the mature miRNA (Saini et al.,
2007; Zhou et al., 2007). DNA methylation status was
established by PCR analysis of bisulﬁte-modiﬁed genomic
DNA, which induces chemical conversion of unmethylated,
but not methylated, cytosine to uracil. Two procedures were
used. First, methylation status was analyzed by bisulﬁte
genomic sequencing of the corresponding CpG islands. Eight
independent clones were analyzed. The second analysis used
Figure 5 T-UCR CpG island hypermethylation patterns in human tumorigenesis. (a) Methylation-speciﬁc PCR analyses for
Uc.160þ, Uc.283þA and Uc.346þ methylation in primary human tumors from different types. In vitro methylated DNA (IVD) and
normal lymphocytes (NLs) are shown as positive and negative controls for methylated and unmethylated sequences, respectively.
(b) Frequency of Uc.160þ, Uc.283þA and Uc.346þ hypermethylation in primary human tumors from different types, normal
tissues and premalignant lesions (colorectal adenomas). (c) Distribution of Uc.160þ, Uc.283þA and Uc.346þ CpG island
hypermethylation in primary tumors according to the presence or absence of lymph node metastasis. The presence of hypermethylation
of the T-UCRs is signiﬁcantly associated with the existence of metastasis in human malignancies. (d) Observation of an unmethylated
Uc.160þ CpG island in all leukemias that overexpress the miR-155 transcript determined by quantitative RT–PCR in comparison
with the presence of Uc.160þ hypermethylation in all leukemias with low levels of miR-155 (P¼0.01492, Student’s t-test).
CRC, colorectal carcinoma.
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Oncogenemethylation-speciﬁc PCR with primers speciﬁc for either the
methylated or the modiﬁed unmethylated DNA. The primers
used are described in the Supplementary Table 2.
Quantiﬁcation and cellular localization of T-UCRs and miR-155
with real-time PCR
Quantitative RT–PCR was performed to quantify the level of
T-UCRs as described previously (Calin et al., 2007). Each RT
reaction contained 1mg of puriﬁed and DNase-treated (turbo
DNA-free, Ambion, Austin, TX, USA) total RNA, which was
reverse transcribed using Thermoscript RT and gene-speciﬁc
(sense or antisense) primers. cDNA was ampliﬁed using real-
time PCR and SYBR (Applied Biosystems, Foster City, CA,
USA) green detection using PCR primers designed to amplify
the same 40-bp regions as the oligo probe on the microarray.
The primers used are described in Supplementary Table 2.
TaqMan assays were used to quantify the level of miR-155 as
described previously (Lujambio et al., 2008). The relative
amounts of each UCR and miRNA to the control (U6 and
GAPDH, and RNU19, respectively) were determined using
the 2(DDCt) method (Livak and Schmittgen, 2001).
Further details are provided in Supplementary Materials and
methods.
Quantitative chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed as
previously described (Jacinto et al., 2009) using the anti-
trimethyl-K4 histone H3 antibody (ab8580/ab1220; Abcam,
Cambridge, MA, USA) and anti-RNA polymerase II (N20,
SC899; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The primers used are described in Supplementary Table 2.
Further details are provided in Supplementary Materials and
methods.
Chromatin accessibility
Nuclei from each cell line were digested in a series of increasing
MspI restriction enzyme (Roche Molecular Biochemicals,
Mannheim, Germany) concentrations (0, 100 and 400U/ml)
at 371C for 1h. We used the 2(DDCt) method (Livak and
Schmittgen, 2001) to determine relative levels of ampliﬁcation,
using a region in the RIZ gene without MspI targets for
normalization. Values were expressed as the difference relative
to the controls. The primers used are described in Supplemen-
tary Table 2. Further details are provided in Supplementary
Materials and methods.
RACE, cloning and transfection
Transcription start sites for the three studied T-UCRs
(Uc.160þ, Uc.283þA and Uc.346þ) were identiﬁed by
RACE in the 50 direction. The sequences were obtained
independently from DKO and LAN-1 cell lines according to
the manufacturer’s protocol (SMARTerTM RACE cDNA
Ampliﬁcation Kit; Clontech, Palo Alto, CA, USA). The 30 end
of Uc.283þA was localized by primer walking within a region
of B350bp. The primers used in both approaches are
described in Supplementary Table 2. For transfection, the
Uc.283þA expression vector (pCDNA3.1 Uc283þA) was
constructed by cloning the DNA corresponding to Uc.283þA
into a pCDNA3.1 (þ) vector. An empty pCDNA3.1 (þ)
vector was used as a control. HCT-116 cells were transfected
by electroporating 10
7 cells in 0.8ml phosphate-buffered saline
with 40mg of the vector at 250V and 975mF. After
electroporation, cells were washed with phosphate-buffered
saline and seeded in fresh medium.
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